The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.

  title={The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.},
  author={Jerrold H Levy and Penrose S O'Donnell},
  journal={Expert opinion on investigational drugs},
  volume={15 9},
Hereditary angioedema (HAE) manifests as intermittent, painful attacks of submucosal oedema affecting the larynx, gastrointestinal tract or limbs. Currently, acute treatment is available in Europe but not USA, and requires intravenous administration of a pooled blood product. HAE is most likely caused by dysinhibition of the contact cascade, resulting in overproduction of bradykinin. DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 34 extracted citations

Ecallantide in Acute Hereditary Angioedema

BioDrugs • 2011
View 3 Excerpts
Highly Influenced

Antibody-mediated rejection: New approaches in prevention and management.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons • 2018

Health-related quality of life among children with hereditary angioedema.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology • 2017
View 1 Excerpt

Hereditary angioedema: what the gastroenterologist needs to know

Clinical and experimental gastroenterology • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…